title: [New aspects of immunotherapy of malignant melanoma].
abstract: Malignant melanoma is a fatal disease in its terminal stage. Despite of all attempts to prolong the life of the patient with chemo- or chemoimmunotherapies, the course of the disease is rarely affected. Specific immunotherapies with antigen-pulsed DC might be a reason for optimism. DC are professional antigen-presenting cells with a capability to process and present melanoma antigens. First vaccination studies show encouraging results with complete remissions even in progressed cases.
authors: Hautklinik der Johannes Gutenberg-Universität Mainz.
authors: A
authors: A
authors: Enk
mesh_terms: D019496:Cancer Vaccines / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003713:Dendritic Cells / Q000276:immunology / Q000637:transplantation; D006801:Humans; D007167:Immunotherapy; D007372:Interferons / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D008545:Melanoma / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D012878:Skin Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*
chemical_list: D019496:Cancer Vaccines; D007376:Interleukin-2; D007372:Interferons